59th Medical Wing

Presentation of Biomarker Analysis at ASCO

Retrieved on: 
Monday, May 30, 2022
Cancer, MODS, Ernest K. Warburton (US Air Force), Part, Company, Uveal melanoma, Medicine, Fårö, Tams, Patient, Infection, Trauma, 59th Medical Wing, Nature, Stomach, End organ damage, Lymphatic system, Defense, Interferon beta-1a, Antigen presentation, United States Air Force, Cholangiocarcinoma, Thyroid cancer, AIM, Hepatocellular carcinoma, Safety, Ovarian cancer, Injury, Colorectal cancer, Part Two, Immune system, Pancreatic cancer, Nasdaq First North, Neoplasm, Director, Phrase, Growth, Inhibitor, Red blood cell, Vaccine, Pharmaceutical industry

TURKU, Finland and BOSTON, May 30, 2022 /PRNewswire/ -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that new biomarker data from patients treated with bexmarilimab as part of the ongoing phase I/II MATINS (Macrophage Antibody to Inhibit Immune Suppression) trial, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2022 Annual Meeting being held in Chicago, US from June 3 – 7. These data (Abstract #2645) will be featured in the "Developmental Therapeutics—Immunotherapy" session on Sunday, June 5, 2022 at 9:00 AM EDT.

Key Points: 
  • In mouse models, bexmarilimab has successfully blocked or silenced Clever-1, activating antigen presentation and promoting interferon gamma secretion by leukocytes.
  • Beyond immuno-oncology, it offers potential in infectious diseases, vaccine development and more.
  • The ongoing Part II is focused on identifying patients who show an increased number of Clever-1 positive TAMs and exploring safety and efficacy.
  • Data from MATINS have shown that bexmarilimab has the potential to be the first macrophage immune checkpoint therapy.

Faron Announces US Food and Drug Administration and Finnish Medicines Agency Approval to Initiate Phase I/II Bexmarilimab Combination Study in Hematologic Malignancies

Retrieved on: 
Monday, May 16, 2022
Cancer, MODS, Ernest K. Warburton (US Air Force), Company, Medicine, Fårö, Tams, Patient, Infection, Trauma, 59th Medical Wing, Nature, End organ damage, Defense, COVID-19, Interferon beta-1a, Antigen presentation, United States Air Force, AIM, Injury, Immune system, Nasdaq First North, Neoplasm, Director, Phrase, Growth, Red blood cell, Vaccine, Pharmaceutical industry

TURKU, Finland and BOSTON, May 16, 2022 /PRNewswire/ -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, today announces that both the U.S. Food and Drug Administration (FDA) and Finnish Medicines Agency (FIMEA) have cleared Faron's Investigational New Drug (IND) application to begin the Company sponsored BEXMAB study. BEXMAB is a novel Phase I/II study to assess safety, tolerability and preliminary efficacy of bexmarilimab, Faron's wholly-owned investigational precision cancer immunotherapy, in combination with standard of care (SoC) therapy in patients with relapsed acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CML). This marks the first time bexmarilimab will be assessed as part of a clinical study in hematologic malignancies.

Key Points: 
  • In mouse models, bexmarilimab has successfully blocked or silenced Clever-1, activating antigen presentation and promoting interferon gamma secretion by leukocytes.
  • As an immuno-oncology therapy, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules.
  • Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system.
  • Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

Vascular Perfusion Solutions Collaborates with Wyss Institute and U.S. Air Force to Study Compound to Improve Organ Transplant Outcomes

Retrieved on: 
Thursday, April 14, 2022
Wyss Institute, CEO, Travel, Military, Massachusetts Institute of Technology, Research, Medtech, Boston University, Medicine, DARPA, Resuscitation, Biostasis, Injury, Wyss Institute for Biologically Inspired Engineering, Organization, Hospital, GLOBE, Wyss, Perfusion, Tissue, SAN, University of Massachusetts Medical School, University, Solution, Science, Atmosphere of Earth, Heart, Temperature, Tufts University, M.D, Metabolism, Environment, United, Harvard University, US Airways, Massachusetts General Hospital, Oxygen, Beth Israel Deaconess Medical Center, Spaulding Rehabilitation Hospital, Industry, Institute, Therapy, 59th Medical Wing, VPS, Berlin, Medical imaging, Pharmaceutical industry, Design, Engineering, Brigham

We were very excited when the invitation came to partner with the Wyss Institute.

Key Points: 
  • We were very excited when the invitation came to partner with the Wyss Institute.
  • We saw the potential for synergy between the two technologies, and said yes right away, said Mark Muller, J.D., the CEO of VPS.
  • However, this time becomes a significant obstacle when organs must travel long distances from their donors to their recipients.
  • Vascular Perfusion Solutions, Inc. is a development and early-stage company, formed for the purpose of commercializing new, unique, and innovative oxygenated perfusion preservation and resuscitation solutions for the bodys limbs, organs, and other vascularized tissue.

Faron Obtains Debt Funding from IPF Partners

Retrieved on: 
Monday, February 28, 2022
Uveal melanoma, Phrase, Part Two, Growth, Neoplasm, End organ damage, Fårö, Immune system, Trauma, Defense, Ernest K. Warburton (US Air Force), COVID-19, Interferon beta-1a, Company, Red blood cell, Hepatocellular carcinoma, Safety, Nature, Pancreatic cancer, Cancer, AIM, Tams, Director, 59th Medical Wing, Medicine, Nasdaq First North, Antigen presentation, MODS, Colorectal cancer, Infection, Part, United States Air Force, Stomach, Patient, Injury, Inhibitor, Thyroid cancer, Ovarian cancer, Cholangiocarcinoma, Pharmaceutical industry

TURKU, Finland and BOSTON, Feb. 28, 2022 /PRNewswire/ -- Faron Pharmaceuticals Ltd. (AIM: FARN) (First North: FARON), a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces that it has entered into a secured debt agreement ("Funding Agreement") with IPF Partners ("IPF") to advance and accelerate its pipeline programs. The first tranche of EUR 10 million is agreed to be drawn today and is to be repaid quarterly over a five year term. Subject to certain conditions being met, Faron may have access to an additional EUR 20 million in funding until mid-2023 on a four and one-half year term under the Funding agreement. The Funding Agreement is subject to minimum cash and gross gearing covenants.

Key Points: 
  • In mouse models, bexmarilimab has successfully blocked or silenced Clever-1, activating antigen presentation and promoting interferon gamma secretion by leukocytes.
  • As an immuno-oncology therapy, bexmarilimab has potential as a single-agent therapy or in combination with other standard treatments including immune checkpoint molecules.
  • The ongoing Part II is focused on identifying patients who show an increased number of Clever-1 positive TAMs and exploring safety and efficacy.
  • Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system.

Warrior Centric Health Launches Population Health Mission with Air Force's 59th Medical Wing

Retrieved on: 
Tuesday, October 12, 2021
Defense Health Agency, Twitter, United States Air Force, WCH, Small Business Innovation Research, Air Force Research Laboratory, 59th Medical Wing, Air force, AFRL, Air Force Medical Operations Agency, MDW, LinkedIn, Traction, Small business, Population, Minnesota, Microsoft, Health, Hospital, Medicine, Data science, Business, AFWERX, Defense, CEO, The, Founder, SBIR, Student, Research, Risk management

ELLICOTT CITY, Md., Oct. 12, 2021 /PRNewswire/ -- Warrior Centric Health (WCH) has launched work on a contract to adapt its commercial population health management solution to serve the Air Force's flagship 59th Medical Wing, located at Joint Base San Antonio, Texas.

Key Points: 
  • ELLICOTT CITY, Md., Oct. 12, 2021 /PRNewswire/ -- Warrior Centric Health (WCH) has launched work on a contract to adapt its commercial population health management solution to serve the Air Force's flagship 59th Medical Wing, located at Joint Base San Antonio, Texas.
  • A key objective of Quad Aim is implementation of population-based health strategies that specifically target active-duty service members, retirees, and their families who receive care in Military Health Facilities (MTFs).
  • Says Ron Steptoe, CEO and Founder of Warrior Centric Health:
    "Everyone at Warrior Centric Health is looking forward to working with the 59th Medical Wing.
  • The 59th Medical Wing is the largest medical wing in the Air Force, composed of six groups across the $1.2 billion San Antonio Military Health System, Joint Base San Antonio.